EPIRUS Biopharmaceuticals Performance
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and EPIRUS Biopharmaceutica are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days EPIRUS Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, EPIRUS Biopharmaceutica is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Total Cashflows From Investing Activities | 841 K |
EPIRUS |
EPIRUS Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 0.01 in EPIRUS Biopharmaceuticals on October 24, 2024 and sell it today you would earn a total of 0.00 from holding EPIRUS Biopharmaceuticals or generate 0.0% return on investment over 90 days. EPIRUS Biopharmaceuticals is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than EPIRUS, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
EPIRUS Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EPIRUS Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as EPIRUS Biopharmaceuticals, and traders can use it to determine the average amount a EPIRUS Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EPRSQ |
Based on monthly moving average EPIRUS Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EPIRUS Biopharmaceutica by adding EPIRUS Biopharmaceutica to a well-diversified portfolio.
EPIRUS Biopharmaceutica Fundamentals Growth
EPIRUS Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of EPIRUS Biopharmaceutica, and EPIRUS Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EPIRUS Pink Sheet performance.
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (37.45) % | |||
| Current Valuation | (6 M) | |||
| Shares Outstanding | 26.18 M | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 701 K | |||
| EBITDA | (54.6 M) | |||
| Cash And Equivalents | 20.86 M | |||
| Cash Per Share | 0.80 X | |||
| Total Debt | 14.85 M | |||
| Debt To Equity | 0.57 % | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (46.58 M) | |||
| Earnings Per Share | (2.52) X | |||
| Total Asset | 72.26 M | |||
| Retained Earnings | (155.03 M) | |||
| Current Asset | 25.69 M | |||
| Current Liabilities | 32.63 M | |||
About EPIRUS Biopharmaceutica Performance
Assessing EPIRUS Biopharmaceutica's fundamental ratios provides investors with valuable insights into EPIRUS Biopharmaceutica's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the EPIRUS Biopharmaceutica is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts. EPIRUS BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 73 people.Things to note about EPIRUS Biopharmaceuticals performance evaluation
Checking the ongoing alerts about EPIRUS Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for EPIRUS Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| EPIRUS Biopharmaceutica is not yet fully synchronised with the market data | |
| EPIRUS Biopharmaceutica has some characteristics of a very speculative penny stock | |
| EPIRUS Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| EPIRUS Biopharmaceuticals has accumulated 14.85 M in total debt with debt to equity ratio (D/E) of 0.57, which is about average as compared to similar companies. EPIRUS Biopharmaceuticals has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist EPIRUS Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, EPIRUS Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like EPIRUS Biopharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for EPIRUS to invest in growth at high rates of return. When we think about EPIRUS Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 701 K. Net Loss for the year was (52.19 M) with profit before overhead, payroll, taxes, and interest of 576 K. | |
| EPIRUS Biopharmaceuticals has accumulated about 20.86 M in cash with (46.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing EPIRUS Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EPIRUS Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining EPIRUS Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EPIRUS Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of EPIRUS Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EPIRUS Biopharmaceutica's pink sheet. These opinions can provide insight into EPIRUS Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |